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Abstract
Interleukin-15 (IL-15) is a cytokine that is highly expressed in skeletal muscle tissue, and that has anabolic eﬀects on skeletal
muscle protein dynamics both in vivo and in vitro. Additionally, administration of IL-15 to rats and mice inhibits white adipose
tissue deposition. To determine if the action of IL-15 on adipose tissue is direct, the capacity of cultured murine 3T3-L1
preadipocytes and adipocytes to respond to IL-15 was examined. IL-15 administration inhibited lipid accumulation in
diﬀerentiating 3T3-L1 preadipocytes, and stimulated secretion of the adipocyte-speciﬁc hormone adiponectin by diﬀerentiated
3T3-L1 adipocytes. The latter observation constitutes the ﬁrst report of a cytokine or growth factor that stimulates adiponectin
production. IL-15 mRNA expression by cultured 3T3-L1 adipogenic cells and C2C12 murine skeletal myogenic cells was also
examined. Quantitative real-time PCR indicated IL-15 mRNA was expressed by C2C12 skeletal myogenic cells, and was
upregulated more than 10-fold in diﬀerentiated skeletal myotubes compared to undiﬀerentiated myoblasts. In contrast, 3T3-L1 cells
expressed little or no IL-15 mRNA at either the undiﬀerentiated preadipocyte or diﬀerentiated adipocyte stages. These ﬁndings
provide support for the hypothesis that IL-15 functions in a muscle-to-fat endocrine axis that modulates fat:lean body composition
and insulin sensitivity.
 2005 Published by Elsevier Ltd on behalf of International Federation for Cell Biology.
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The cytokine interleukin-15 (IL-15) is highly ex-
pressed at the mRNA level in skeletal muscle tissue
(Grabstein et al., 1994). Previous in vitro experiments
have demonstrated that IL-15 has anabolic eﬀects on
skeletal muscle protein dynamics (Quinn et al., 1995,
2002), conferred by a mechanism which is distinct from
that of the well-characterized anabolic factor insulin-like
growth factor-I (IGF-I). In addition, IL-15 administra-
tion signiﬁcantly reduces the rate of muscle protein
degradation and inhibits skeletal muscle wasting in an in
vivo rodent model of cancer cachexia (Carbo´ et al.,
2000). These ﬁndings suggest IL-15 may function as an
autocrine anabolic mediator of skeletal muscle growth.
In studies investigating the eﬀects of IL-15 on skeletal
muscle, it was also observed that IL-15 administration
induced 33% reduction in adipose tissue deposition in
growing rats, with no reduction in food intake (Carbo´
et al., 2000, 2001). Such observations cannot distinguish
between a direct eﬀect of IL-15 on adipose tissue or an
indirect eﬀect on other tissues and/or hormones
regulating adipogenesis or energy expenditure. Another
in vivo study utilizing obese rodent models (obese
Zucker rats and ob/ob mice) reported that sensitivity to
the fat-inhibiting eﬀects of IL-15 was associated with
expression levels of mRNA for a key signaling subunit
of the IL-15 receptor in adipose tissue (Alvarez et al.,
2002). These data suggest IL-15 reduces adipose tissue
mass by a direct mechanism.
The present study was performed to determine if IL-
15 has direct eﬀects on a cultured adipogenic cell line.
To this end, we examined the eﬀects of recombinant
human (rh) IL-15 on lipid deposition and adiponectin
secretion (Wolf, 2003) in cultured murine 3T3-L1 cells.
We also examined IL-15 mRNA expression by cultured
murine 3T3-L1 and C2C12 skeletal myogenic cells. The
present data provide evidence to support the involve-
ment of IL-15 in a muscle-to-fat endocrine axis (Carbo´
et al., 2001), and may contribute to a better un-
derstanding of the control of lean/fat body composition,
with implications for the pathophysiology and treatment
of associated conditions, such as obesity, insulin re-
sistance and type 2 diabetes.
2. Materials and methods
2.1. Cell culture
C2C12 skeletal myogenic and 3T3-L1 adipogenic
murine cell lines were obtained from the American Type
Culture Collection (ATCC; Manassas, VA, USA). Cells
from both lines were used for experiments at 2e3
passages. For expansion and storage, cell lines
were cultured in 10% fetal bovine serum (FBS;Hyclone, Logan, UT, USA) in high glucose formulation
Dulbecco’s minimal essential medium (DMEM; Sigma,
St. Louis, MO, USA) and cells were stored frozen
at 135 C in 20% FBS/DMEM containing 10%
dimethylsulfoxide (DMSO; Sigma). For analysis,
3T3-L1 preadipocytes were plated in 1 ml 10% FBS/
DMEM in 24-well plates (Costar, Cambridge, MA,
USA) at 105 cells per well, resulting in conﬂuent cultures
by the next day (considered day 0 of culture). To induce
diﬀerentiation (Engelman et al., 1998), the medium was
changed to 10% FBS/DMEM containing 160 nM
insulin (Sigma), 0.25 mM dexamethasone (Sigma), and
0.5 mM 3-isobutyl-1-methylxanthine (Sigma). After an
additional 48 h (day 2), medium was changed to 10%
FBS/DMEM containing 160 nM insulin. Cultures were
treated with 0e10 ng/ml rhIL-15 (R&D Systems,
Minneapolis, MN, USA) either continuously for 4 days
(0e96 h of culture) with replenishment of rhIL-15 at 48
h with the medium change, or for 48 h periods, days
0e2, 2e4, or 4e6 of culture. The latter protocol was
utilized to determine the eﬀects of rhIL-15 on lipid
deposition and adiponectin secretion at speciﬁc periods
of adipogenic diﬀerentiation, with days 0e2 represent-
ing undiﬀerentiated preadipocytes, days 2e4 represent-
ing mid-diﬀerentiation preadipocytes, and days 4e6
representing diﬀerentiated adipocytes.
For analysis of skeletal myogenic cultures, C2C12
myoblasts were plated onto 24-well culture plates at
105 cells per well in 10% FBS/DMEM and allowed to
attach overnight. To induce diﬀerentiation, medium was
changed to a lower serum concentration, 0.5% FBS/
DMEM, at 24 h after plating (considered day 0). Cells
commenced diﬀerentiation and fusion into post-mitotic
myotubes on day 2, and cultures contained a prepon-
derance of diﬀerentiated myotubes by day 5.
2.2. Assay of lipid deposition
Neutral lipid deposition was assessed in 3T3-L1
cultures using a modiﬁcation of the procedure of
Kasturi and Joshi (1982). At speciﬁc time points (days
2, 4, or 6), cultures were rinsed once with PBS at 37 C
and ﬁxed with 10% formalin in PBS overnight at room
temperature. Cultures were rinsed sequentially with
dH2O and 70% ethanol, then stained for 25 min with
ﬁltered Oil Red-O solution, 6 parts Oil Red-O-saturated
isopropanol (Sigma) in 4 parts dH2O. Stained cultures
were rinsed sequentially with 70% ethanol and dH2O,
and lysed with 4% nonidet P-40 (Calbiochem, La Jolla,
CA, USA) in isopropanol on a rotary shaker for 15 min.
Absorbance of the dispersed dye at 544 nm was read
photometrically using a Victor2 microplate reader
(Perkin-Elmer Wallac, Gaithersburg, MD, USA). Re-
sults shown represent the mean of three replicates at
each time point and/or concentration of rhIL-15, with
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treatments determined using Student’s t-tests.
2.3. DNA assay
DNA content per well was assessed in 3T3-L1
adipogenic cultures by measuring Hoechst 33258 dye
(bisbenzimide; Sigma) ﬂuorescence as previously de-
scribed (Haugk et al., 2000). Brieﬂy, cells were rinsed
once with DMEM, ﬁxed for 5 min with 70% ethanol/
formalin/acetic acid (20:2:1) at 4 C, then rinsed 3!
with DMEM and 2! with PBS. Cells were exposed to
1 mg/ml Hoechst 33258 dye in standard saline citrate for
30 min and analyzed using the ﬂuorescence feature of
the Victor2 microplate reader. Results shown represent
the mean values for three wells at each concentration of
rhIL-15, with diﬀerences between control and each
concentration of rhIL-15 determined using Student’s
t-tests.
2.4. Adiponectin secretion
Adiponectin was assayed in culture medium collected
fromdiﬀerentiating 3T3-L1 adipogenic cultures after 48 h
periods of rhIL-15 exposure (0e10 ng/ml), days 0e2,
2e4, or 4e6 of culture in 10% FBS/DMEM, plus the
induction factors added according to the schedule
outlined above. This protocol was utilized to separate
the eﬀects of rhIL-15 on 3T3-L1 diﬀerentiation (which
could in turn aﬀect adiponectin secretion) from the
eﬀects of rhIL-15 on adiponectin secretion at each stage
of diﬀerentiation. At each time point, medium samples
were collected, stored frozen at 20 C, and thawed
immediately prior to analysis. Culture wells from which
medium samples were collected were rinsed and used for
analysis of lipid deposition as outlined above. Media
adiponectin concentrations were determined using
a mouse adiponectin radioimmunoassay (RIA) kit
(Linco, St. Charles, MO, USA) utilizing 125I-labeled
murine adiponectin and an anti-adiponectin rabbit
antiserum to measure adiponectin concentrations
by the double antibody/PEG (polyethylene glycol)
technique. Standards over the range of 1e100 ng/ml
were prepared using recombinant murine adiponectin.
Medium samples were assayed undiluted or diluted 1:4,
yielding an eﬀective range of 1e400 ng/ml. The intra-
assay and inter-assay coeﬃcients of variation at
adiponectin concentrations in the range of 3e12 mg/ml
were 3.7e4.4% and 6.6e8.2%, respectively. Medium
control samples consisted of 10% FBS/DMEM in-
cubated in 24-well plates with no cells along with the
experimental samples. All medium control samples
exhibited immunoreactivity of less than 2 ng/ml
adiponectin. Results shown represent the mean values
for three wells at each concentration of rhIL-15 added
to the cultures for each time period, with diﬀerencesbetween control (0 ng/ml IL-15 added) and each
concentration of rhIL-15 determined using Student’s
t-tests.
2.5. Quantitative real-time PCR analysis of IL-15
mRNA expression
C2C12 myogenic cultures and 3T3-L1 adipogenic
cultures were established and induced to diﬀerentiate as
described above. RNA was harvested at the undiﬀeren-
tiated preadipocyte (day 0) or myoblast (day 0) stages,
mid-diﬀerentiation stages (day 2 for 3T3-L1 and day
3 for C2C12), and diﬀerentiated adipocyte or myotube
stages (day 4 for 3T3-L1 and day 5 for C2C12) of
culture. Total RNA was isolated and puriﬁed from
C2C12 and 3T3-L1 cultures using the RNeasy Fibrous
Tissue or Lipid Tissue Kits (Qiagen, Valencia, CA,
USA), respectively. RNA samples were treated on
column with 30 Kunitz units DNase I (Qiagen) to
remove residual genomic DNA, then quantiﬁed using
the RiboGreen RNA Quantitation Kit (Molecular
Probes, Eugene, OR, USA). cDNA was reverse tran-
scribed from 1 mg total RNA using the Bio-Rad iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA).
Quantitative real-time polymerase chain reaction
(PCR) analysis of IL-15 mRNA expression was
performed using a Bio-Rad iCycler, and IL-15 mRNA
expression normalized to 18S ribosomal RNA expres-
sion for each sample. Total RNA (1 mg) was run in 20 ml
reactions using a blend of oligo dT and random hexamer
primers and a modiﬁed MMLV-derived reverse tran-
scriptase (RT; Bio-Rad). Reaction cycles were 5 min at
25 C, 30 min at 42 C, and 5 min at 85 C. Each cDNA
reaction was diluted 5!, along with a calibrator sample
containing the transcript of interest, and run in 50 ml
Bio-Rad SYBR Green reactions using 200 mM primers
designed by Beacon Designer software (BioSoft In-
ternational, Palo Alto, CA, USA). Primers for murine
IL-15 mRNA, which detected either of two RNA splice
variants coding for identical mature IL-15 peptides
(Fehniger and Caligiuri, 2001), were: forward 5#-CAG
CAC TCT GTC TTC TAA CAA GAA-3#; reverse 5#-
TCT GTG AAG GTT TTC TCC TCC A-3#. Primers
for 18S ribosomal RNA, used as the ‘‘housekeeping’’
gene, were: forward 5#-GCG AAT GGC TCA TTA
AAT CAG TTA-3#; reverse 5#-TGG TTT TGA TCT
GAT AAA TGC ACG-3#.
Reactions were processed using one initial denatur-
ation cycle (5 min at 95 C), then 40 cycles of
denaturation (30 s at 95 C), annealing (30 s at 61 C)
and ampliﬁcation (30 s at 72 C) followed by melt curve
determination consisting of one denaturation cycle
(1 min at 95 C), annealing (one cycle for 1 min at
62 C), then 68 cycles (10 s each at 61 C to 95 C). The
18S ribosomal RNA primer pair reaction was run on
every sample for template content normalization
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of interest was run to yield a standard curve for each
primer set, and individual primer reaction eﬃciencies
were calculated from this curve using the iCycler
software. The iCycler software calculated a threshold
cycle for each sample; threshold cycles and primer pair
eﬃciencies were used in the 2DDCT method (Livak and
Schmittgen, 2001) to yield diﬀerences in IL-15 mRNA
expression as normalized to the 18S housekeeping gene.
3. Results
3.1. Eﬀects of IL-15 on lipid deposition in 3T3-L1
adipogenic cultures
Incubation of 3T3-L1 cells with 2e10 ng/ml rhIL-15
from days 0e4 of culture resulted in approximately 20%
decreases ( p!0.001, t-tests) in Oil Red-O staining
compared to cultures treated with vehicle alone
(Fig. 1A). DNA content per well did not diﬀer among
treatment groups (Fig. 1B), indicating the decrease in
lipid deposition was not an artifact of reduced cell
numbers due to cytokine toxicity. The eﬀects of rhIL-15
on 3T3-L1 lipid deposition at speciﬁc periods of culture,
representing the progression from undiﬀerentiated
preadipocytes (days 0e2) to mid-diﬀerentiation preadi-
pocytes (days 2e4) to diﬀerentiated adipocytes (days
4e6), were also determined (Fig. 1C). When 3T3-L1
cultures were treated with rhIL-15 from days 0 to 2, Oil
Red-O staining was reduced more than 50% ( p!0.05).
In contrast, rhIL-15 treatment of cultures from days 2 to
4 resulted in only a 15% inhibition of lipid deposition,
which was nevertheless signiﬁcant ( p!0.05). Lipid
deposition rose dramatically between days 4 and 6.
However, rhIL-15 exposure from days 4 to 6 did not
result in a signiﬁcant decrease in Oil Red-O staining,
indicating IL-15 does not inhibit lipid deposition by
diﬀerentiated 3T3-L1 adipocytes.
3.2. Eﬀects of IL-15 on adiponectin secretion in
3T3-L1 adipogenic cultures
To determine if IL-15 could modulate the endocrine
function of diﬀerentiated adipocytes, the eﬀects of
rhIL-15 treatment on secretion of adiponectin were
determined by RIA of culture medium (Fig. 2). Adipo-
nectin concentrations in medium collected from cultures
during days 0e2 were equivalent to those in medium
control samples (incubated without cells), indicating
3T3-L1 preadipocytes secrete undetectable amounts of
adiponectin (not shown). Treatment of preadipocytes
with rhIL-15 on days 0e2 had no eﬀect on adiponectin
secretion (Fig. 2A). Adiponectin secretion from day 2e4
cultures was low but detectable, and was also unaﬀectedby rhIL-15 treatment (Fig 2A). Adiponectin secretion
increased dramatically by days 4e6, coincident with
adipocyte diﬀerentiation (Fig. 2A). Treatment of day 4e6
cultures with 10 ng/ml rhIL-15 signiﬁcantly increased
adiponectin secretion from 71.5G 3.8 ng/ml to
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Fig. 1. Eﬀects of rhIL-15 on lipid deposition in diﬀerentiating 3T3-L1
preadipocyte cultures. (A) Lipid deposition assessed for 4 days
following induction of adipocyte diﬀerentiation; cultures were exposed
continuously to 0e10 ng/ml rhIL-15. (B) DNA content per well
assessed for 4 days following induction of adipocyte diﬀerentiation;
cultures were exposed continuously to 0e10 ng/ml rhIL-15. (C) Eﬀects
of rhIL-15 administered at speciﬁc 48 h periods in culture. Exposure
periods (0e2, 2e4, 4e6) indicate days of culture following addition of
inducers,G2 ng/ml rhIL-15, followed by processing of cultures at days
2, 4, or 6, respectively. Lipid deposition was assessed by Oil Red-O
staining, assayed photometrically; DNA content was assessed by
Hoechst 33258 dye ﬂuorescence. For all panels, each bar represents the
meanGSEM of three replicates, with diﬀerences between control (no
rhIL-15) and rhIL-15-treated cultures determined by t-tests (*p!0.05;
***p!0.001).
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on adiponectin secretion by 3T3-L1 adipocytes was
concentration-dependent with a threshold of 5 ng/ml
(Fig. 2B), while lipid content in adipocyte cultures
treated with rhIL-15 on days 4e6 was unchanged
(Fig. 2C).
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Fig. 2. Eﬀects of IL-15 on adiponectin secretion in 3T3-L1 adipogenic
cultures. (A) Eﬀects of 10 ng/ml rhIL-15 administered at speciﬁc 48 h
periods in culture. Exposure periods (0e2, 2e4, 4e6) indicate days of
culture following addition of inducers, G10 ng/ml rhIL-15, followed
by processing of cultures at days 2, 4, or 6, respectively. (B)
Adiponectin secretion by 3T3-L1 adipocytes exposed to 0e10 ng/ml
rhIL-15 on days 4e6 following induction of adipocyte diﬀerentiation.
(C) Lipid content of 3T3-L1 adipocytes exposed to 0e10 ng/ml rhIL-
15 on days 4e6 following induction of adipocyte diﬀerentiation.
Adiponectin secretion was determined by RIA of culture medium; lipid
deposition was determined by microplate-based assay of oil Red-O
staining. For all panels, each bar represents the meanGSEM of three
replicates, with diﬀerences between control (no rhIL-15) and rhIL-15-
treated cultures determined by t-tests (*p!0.05; ***p!0.001).3.3. Expression of IL-15 mRNA in cultured skeletal
myogenic and adipogenic cells
IL-15 mRNA expression in cultured skeletal myo-
genic and adipogenic cells has not been characterized
with respect to diﬀerentiation stages. Fig. 3 shows real-
time quantitative PCR analysis of IL-15 mRNA
expression by cultured 3T3-L1 adipogenic cells and
C2C12 skeletal myogenic cells. For both cell types, IL-
15 mRNA expression was assessed at the undiﬀerenti-
ated precursor cell (preadipocyte, myoblast) stages,
at mid-diﬀerentiation, and at the diﬀerentiated cell
(adipocyte, myotube) stages. C2C12 myoblasts (culture
day 0) expressed IL-15 mRNA which was detectable
after 32.5 cycles of PCR. By the mid-diﬀerentiation and
diﬀerentiated myotube stages (days 3e5 of culture), IL-
15 mRNA expression increased more than 10-fold, and
was signiﬁcantly diﬀerent from the level of IL-15
mRNA expression in undiﬀerentiated myoblast cultures
( p! 0.01, t-tests; not indicated in Fig. 3). In contrast,
IL-15 mRNA expression by 3T3-L1 cells was detected at
34.7e38 cycles of PCR, equivalent to background levels
and signiﬁcantly lower than the levels detected in C2C12
cells at equivalent stages of diﬀerentiation ( p!0.01,
t-tests). These ﬁndings indicate cultured skeletal myo-
genic cells express IL-15 mRNA which is upregulated
concurrent with diﬀerentiation into myotubes, whereas
cultured 3T3-L1 preadipocytes and adipocytes express
little or no IL-15 mRNA under these conditions.
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Fig. 3. Expression of IL-15 mRNA by cultured mouse 3T3-L1
adipogenic and C2C12 skeletal myogenic cell lines, assessed by
quantitative real-time PCR. For 3T3-L1 cultures, RNA was harvested
at the undiﬀerentiated preadipocyte (day 0), mid-diﬀerentiation
(day 2), and diﬀerentiated adipocyte (day 4) stages of culture. For
C2C12 cultures, RNA was harvested at the undiﬀerentiated myoblast
(day 0), mid-diﬀerentiation (day 3), and diﬀerentiated myotube (day 5)
stages of culture. Each bar represents the meanG SEM of three
replicates, with diﬀerences between 3T3-L1 and C2C12 cultures at each
stage determined by t-tests (**p! 0.01; ***p! 0.001). IL-15 mRNA
expression by C2C12 cultures also diﬀered signiﬁcantly between
undiﬀerentiated and mid-diﬀerentiated stages ( p! 0.001, t-test), and
between undiﬀerentiated and diﬀerentiated stages ( p! 0.01), not
indicated by asterisks in the ﬁgure.
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Previous in vivo studies suggested that IL-15 inhibits
fat deposition via a direct action on adipose tissue in
rodents (Alvarez et al., 2002). The present study utilized
the murine 3T3-L1 preadipocyte cell line to investigate
the direct action of IL-15 on cultured adipogenic cells.
Incubation of 3T3-L1 preadipocytes with rhIL-15
inhibited lipid deposition by more than 50%, an eﬀect
which decreased as diﬀerentiation progressed. IL-15 had
no eﬀect on lipid content in diﬀerentiated 3T3-L1
adipocytes; however, IL-15 instead acted to stimulate
secretion of the adipocyte-speciﬁc hormone, adiponec-
tin, by these cells. These observations demonstrate IL-15
can exert direct actions on 3T3-L1 cells at both the
preadipocyte and diﬀerentiated adipocyte stages.
This study also examined IL-15 mRNA expression by
cultured mouse adipogenic and skeletal myogenic cell
lines. The results are in agreement with previous in vivo
studies reporting high expression of IL-15 mRNA by
skeletal muscle tissue (Grabstein et al., 1994). Further-
more, IL-15 mRNA expression by a determined skeletal
myogenic cell line and its upregulation during diﬀeren-
tiation, suggests that muscle cells themselves, as opposed
to intramuscular vascular, connective tissue, or immune
inﬁltrating cells (Weisberg et al., 2003; Xu et al., 2003),
express IL-15 mRNA. In contrast, we observed little or
no IL-15 mRNA expression by cultured 3T3-L1 cells, at
any stage of diﬀerentiation, under the conditions tested.
Our results do not exclude the possibility of IL-15
production by adipocytes or adipose tissue under other
conditions. Indeed, a recent report indicated explanted
porcine adipocytes express IL-15 mRNA when stimu-
lated by interferon-gamma (Ajuwon et al., 2004).
However, our ﬁndings demonstrate vastly diﬀerent
basal levels of IL-15 mRNA expression between
cultured adipocyte and muscle cell lines. Diﬀerences in
IL-15 expression levels between adipocyte cell lines and
explanted primary adipocytes could be due to the
presence of macrophage-like inﬁltrating cells in the
primary cultures (Weisberg et al., 2003; Xu et al., 2003).
In addition to its primary role as an energy storage
depot, the role of adipose tissue as an endocrine organ is
increasingly recognized (Wolf, 2003; Steppan and Lazar,
2002; Sonnenberg et al., 2004; Havel, 2004). Adipose
tissue secretes a number of biologically active factors,
termed adipocytokines, which include adiponectin,
leptin, tumor necrosis factor-alpha (TNF-a), interleu-
kin-6 (IL-6), and resistin (Wolf, 2003; Steppan and
Lazar, 2002; Sonnenberg et al., 2004; Havel, 2004).
These secreted proteins can act directly on peripheral
tissues, such as skeletal muscle, to regulate processes
such as protein turnover and insulin sensitivity (Fig. 4,
upper panel), and can also act by regulating central
nervous tissue pathways which regulate appetite, feeding
behavior, and energy expenditure (Wolf, 2003; Steppanand Lazar, 2002; Sonnenberg et al., 2004; Havel, 2004).
The results of our study support the model originally
proposed by Carbo´ et al. (2001), suggesting that muscle
tissue may in turn secrete IL-15, which acts to inhibit
adipose tissue deposition (Fig. 4, lower panel). The
present study provides evidence of a direct eﬀect of
IL-15 on preadipocytes and adipocytes, and further
indicates that IL-15 can modulate adipose tissue
endocrine function, e.g. adiponectin secretion.
Further conﬁrmation of the proposed model of
a muscle-to-fat endocrine axis will require in vivo
studies and examination of IL-15 protein secretion
patterns. The patterns of IL-15 mRNA expression by
cultured adipogenic and skeletal myogenic cell lines
observed in the present study support this model.
Moreover, multiple tissue Northern blots indicated
skeletal muscle and placenta are the major sites of IL-
15 mRNA expression in vivo (Grabstein et al., 1994).
The IL-15 mRNA isoform expressed in skeletal muscle
is the form believed to be more readily secreted
(Fehniger and Caligiuri, 2001). However, it is not yet
known whether adipose tissue in vivo is exposed to
biologically relevant concentrations of IL-15 produced
by muscle. Recent studies of mice which carried a
muscle-speciﬁc deletion of the peroxisome proliferator-
activated receptor-gamma (PPARg) gene suggested this
deletion indirectly aﬀected secretion of an unidentiﬁed,
muscle-derived hormone which in turn aﬀected adipose
tissue (Hevener et al., 2003). Our ﬁndings suggest IL-15
could be this putative factor.
Fig. 4. Models for peripheral control of fat and muscle. (A) Previous
model based on studies showing growth factors/hormones released
from white adipose tissue aﬀect skeletal muscle. (B) New model,
originally proposed by Carbo´ et al. (2001), suggesting muscle-derived
IL-15 may play a role in modulating white adipose tissue mass and/or
function.
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a number of non-lymphoid tissues, including heart,
lung, liver, kidney, brain, and testes (Fehniger and
Caligiuri, 2001). Along with interleukin-2, an important
role for IL-15 is to support the development of several
types of T lymphocytes, particularly natural killer and
CD8C (‘‘memory T’’) cells (Fehniger and Caligiuri,
2001). Due to these actions, IL-15 inhibits lethality in
murine models of infectious diseases such as retrovirus-
induced acquired immunodeﬁciency syndrome (Ume-
mura et al., 2002) and herpes simplex virus infection
(Tsunobuchi et al., 2000). Additionally, IL-15 has
proinﬂammatory activity in several mouse models of
autoimmune diseases, such as rheumatoid arthritis and
inﬂammatory bowel disease (McInnes et al., 1997;
Vainer et al., 2000). However, in other systems, such
as a murine model of nephritis, IL-15 exerts anti-
inﬂammatory activity (Shinozaki et al., 2002). In several
in vitro and in vivo systems, IL-15 inhibits the pro-
inﬂammatory and pro-apoptotic actions of TNF-a (e.g.,
Bulfone-Paus et al., 1999; Hiromatsu et al., 2003).
Increased production of the proinﬂammatory adipo-
cytokines IL-6 and TNF-a during obesity has been
mechanistically linked to insulin resistance (Weisberg
et al., 2003; Xu et al., 2003; Ajuwon et al., 2004;
Sonnenberg et al., 2004; Lyon et al., 2003). TNF-a and
IL-6 inhibit adiponectin mRNA and protein secretion
(Havel, 2004; Maeda et al., 2001; Fasshauer et al., 2003),
while the present study showed IL-15 stimulates
adiponectin secretion from cultured adipocytes. In
skeletal muscle, IL-6 and TNF-a exert catabolic actions,
inhibiting skeletal myoblast diﬀerentiation and stimu-
lating muscle ﬁber protein degradation (Reid and Li,
2001; Tsujinaka et al., 1995). In contrast, IL-15 exerts
anabolic actions in skeletal muscle in vivo and in vitro
via inhibition of muscle ﬁber protein degradation
(Quinn et al., 2002; Carbo´ et al., 2000). The opposing
actions of IL-15 and TNF-a on muscle protein
degradation and adiponectin secretion by adipocytes
suggests that IL-15 may function to inhibit or oppose
TNF-a-mediated pathways in both skeletal muscle and
adipose tissue.
An important ﬁnding of this study was the stimula-
tion of adiponectin secretion observed during incuba-
tion of diﬀerentiated 3T3-L1 cells in the presence of
IL-15. Adiponectin is a secreted protein produced ex-
clusively by adipocytes in most physiological conditions
(Havel, 2004; Pajvani and Scherer, 2003; Delaigle et al.,
2004). Circulating levels of adiponectin are negatively
correlated with visceral adiposity and insulin resistance
in both rodents and humans (Wolf, 2003; Sonnenberg
et al., 2004; Havel, 2004; Weyer et al., 2001; Cnop et al.,
2003). Adiponectin exerts actions on both liver and
skeletal muscle, where it activates AMP-activated pro-
tein kinase and stimulates fatty acid oxidation, resulting
in improved insulin sensitivity (Yamauchi et al., 2001,2002). Adiponectin may also have actions in the central
nervous system to increase energy expenditure (Qi et al.,
2004). In addition, adiponectin has direct anti-inﬂam-
matory actions on vascular endothelium and may
protect against the progression of atherosclerosis (Havel,
2004; Yamauchi et al., 2003).
Due to the known insulin-sensitizing and anti-
atherosclerotic actions of adiponectin, the regulation
of adiponectin expression and secretion is of consider-
able interest. The insulin-sensitizing thiazolidenedione
class of PPARg agonists appear to function in part by
stimulating adiponectin expression (Sonnenberg et al.,
2004; Havel, 2004; Maeda et al., 2001). The observation
reported here that IL-15 stimulates adiponectin secre-
tion by cultured 3T3-L1 adipocytes represents the ﬁrst
report of an endogenous cytokine or growth factor
which stimulates adiponectin secretion. These data
suggest that IL-15 could potentially act in vivo to
stimulate adiponectin production by adipose tissue,
which would in turn modulate skeletal muscle metabo-
lism and insulin sensitivity.
The present data demonstrating that IL-15 has direct
eﬀects on cultured 3T3-L1 preadipocytes and adipocytes
provides evidence supporting the involvement of IL-15
in a muscle-to-fat endocrine axis (Carbo´ et al., 2001).
Further investigation of this hypothesis is likely to
provide a better understanding of the control of body
composition and substrate metabolism, with implica-
tions for the pathophysiology and treatment of associ-
ated conditions such as obesity, insulin resistance, and
type 2 diabetes.
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